Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc.

$1.5
-0.07 (-4.46%)
NASDAQ Capital Market
USD, US
Medical - Diagnostics & Research

INBS Price Chart

Basic
Market Cap$7.86M
Price$1.5
52 Week Range1.0-15.24
Beta4.69
Margins
Gross Profit Margin35.56%
Operating Profit Margin-333.15%
Net Profit Margin-326.26%
Valuation (TTM)
P/E Ratio-0.23
Price to Sales Ratio2.05
Price to Book Ratio0.29
PEG Ratio-0.01

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Full-Time Employees

50

IPO Date

2020-12-23T00:00:00.000Z

Description

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Phone

646 828 8258

Address

142 West 57th Street, New York, NY, 10019, US

CIK

0001725430